NCT04916886View on ClinicalTrials.gov

A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups.

NACompletedINTERVENTIONAL
Enrollment

2,021

Participants

Timeline

Start Date

June 3, 2021

Primary Completion Date

July 31, 2022

Study Completion Date

July 31, 2022

Conditions
COVID-19
Interventions
BIOLOGICAL

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml

Containing 0.5E10vp

BIOLOGICAL

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml

Containing 0.3E10vp

Trial Locations (1)

Unknown

Funing Center for Disease Control and Prevention, Yancheng

Sponsors
All Listed Sponsors
collaborator

Jiangsu Province Centers for Disease Control and Prevention

NETWORK

lead

CanSino Biologics Inc.

INDUSTRY

NCT04916886 - A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups. | Biotech Hunter | Biotech Hunter